Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 3/20 | 0.36 |
| ▸ | ABL1 | P00519 | 3/20 | 0.35 |
| ▸ | CCR1 | P32246 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | MC3R | P41968 | 1/20 | 0.34 |
| ▸ | MC1R | Q01726 | 1/20 | 0.34 |
| ▸ | HTRA1 | Q92743 | 2/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4043312 | 0.93 | CTSK (0.51) | CTSKTLR7CCR1CTSLCTSB | |
| SCHEMBL4045138 | 0.92 | CTSK (0.42) | CTSKPREPFAPPDE2ACCR1 | |
| SCHEMBL4039168 | 0.92 | CTSK (0.43) | CTSKPREPFAPCCR1HTRA1 | |
| SCHEMBL4042221 | 0.92 | CTSK (0.46) | CTSKTLR7PREPFAPCCR1 | |
| SCHEMBL4040693 | 0.91 | CTSK (0.44) | CTSKPREPFAPCCR1CTSL | |
| SCHEMBL4040698 | 0.90 | CTSK (0.44) | CTSKPREPFAPCTSLCTSB | |
| SCHEMBL4043416 | 0.90 | CTSK (0.54) | CTSKPREPFAPCCR1CTSL | |
| SCHEMBL4045351 | 0.90 | CTSK (0.44) | CTSKPREPFAPCCR1CTSL | |
| SCHEMBL4041783 | 0.88 | CTSK (0.52) | CTSKTLR7PREPFAPPDE2A | |
| SCHEMBL4039917 | 0.88 | CTSK (0.45) | CTSKPREPFAPCCR1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| EP-1370561-B1 | TETRAHYDRO-PYRAZINO[1,2-A]INDOLES FOR THE TREATMENT OF CENTRAL NERVOUS DISORDERS | HOFFMANN LA ROCHE (CH) | 2009-02-11 | — | — | EP | disclosed |
| US-7253281-B2 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-20070106076-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles | BENTLEY JONATHAN M | 2007-05-10 | — | — | US | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| US-20050239789-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles | BENTLEY JONATHAN M | 2005-10-27 | — | — | US | disclosed |
| EP-1325008-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2005-10-05 | — | — | EP | disclosed |
| US-6933387-B2 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles | HOFFMANN-LA ROCHE INC. (US) | 2005-08-23 | — | — | US | disclosed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| US-6844345-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-01-18 | — | — | US | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
| US-20030216401-A1 | Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-20 | — | — | US | disclosed |
| US-20020169163-A1 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. | 2002-11-14 | — | — | US | disclosed |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | VERNALIS RESEARCH LIMITED, A BRITISH COMPANY (GB) | 2002-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239789-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles | GPR119, INSR, GIPR | CTSK 4478/4885TLR7 750/4885PREP 1739/4885 |
| US-20030216401-A1 | Anti-obesity 1, 2, 3, 4, 10, 10a-hexahydropyrazino[1, 2-a] indoles | GPR119, INSR, IRS1 | CTSK 4305/4885TLR7 2601/4885PREP 2018/4885 |
| US-20070106076-A1 | Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles | GPR119, INSR, GIPR | CTSK 4478/4885TLR7 750/4885PREP 1739/4885 |
| US-20020169163-A1 | Piperazine derivatives | GPR119, SLC5A2, DPP4 | CTSK 3959/4885TLR7 2628/4885PREP 43/4885 |
| US-20020035110-A1 | Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles | GPR119, HTR1D, HTR1A | CTSK 4108/4885TLR7 2785/4885PREP 2045/4885 |
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885TLR7 1054/4885PREP 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.